Search Results

Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement Novo Nordisk's GLP-1 for Type II diabetes approved for first-line treatment The Lundbeck Foundation is awarding

This Week in Premium: Sneak Peek Industry insights:  Domain CMO; Pfizer–Metsera; Novo Nordisk strategy

University’s first female Professor of Chemistry, former president of the Royal Society of Chemistry and Founder highly prestigious international award – exemplified by the fact that other winners this year are the co-founders

Breakthroughs this week: Lilly to build $5B manufacturing facility in Virginia; Novo Nordisk flags drug

Submit a logo design by Nov 1st on the Logo Contest page. relatedness Industry News Nobel Laureates Highlight Symposium Celebrating Lefkowitz’s 50 Years at Duke Novo Nordisk stops Ozempic kidney trial after early signs of success Sosei and PharmEnable extend neurological

Health (RHU) SPRINT consortium grant to progress its proprietary CCR8 antibody candidate to the clinic Novo Radioligand Therapy Production Plant Novartis’ Lutathera reduces disease progression risk in GEP-NET trial Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic Dr.

Immunotherapy Drug HTL0039732 Exscientia Business Update for Second Quarter and First Half of 2023 Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes

Most founders are prepared for this on a technical level. Founders feel the pressure to hold everything together. Founders who recognize this early stop asking whether a candidate is impressive. How Founders Can Hire for Survival Without Overengineering It 👉 Once founders recognize that survival For founders, this is not about fixing past hires.

Breakthroughs this week:  5-MeO-DMT: the "God Molecule"; Novo Nordisk looks to next generation of obesity

Submit your logo design by Nov 1st on the Logo Contest page. Company in Immuno-Oncology, Domain Therapeutics, Presents Groundbreaking Advancements at ESMO 2023 Novo Nordisk to Buy Hypertension Treatment from KBP Biosciences Exscientia to Present New Preclinical Data

Breakthroughs this week: Novo Nordisk cuts Ozempic® cost; Nxera launches obesity pipeline; Superluminal–Lilly

December 2021 OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet Prize for Medicine 2022 by the Louis-Jeantet Foundation and the 2022 Benjamin Franklin Medal in Chemistry from The Franklin Institute "Huge congratulations to our founder, Carol Robinson, who has been awarded the prestigious Louis-Jeantet Prize for Medicine 2022 by the Louis-Jeantet Foundation and the 2022 Benjamin

and Provides Business Update Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO Novo Nordisk to Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic

Michel Bouvier, J Silvio Gutkind, and team found that Gαs is essential for GRK selectivity and gene regulation Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address

enable the identification of selective antagonists Industry News Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina semaglutide plant Excellerate Bioscience Announces Site Relocation AI can help

Indeed, incretin-based drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound are advancing diabetes

Raised To Discover And Advance Novel Oral Small Molecule Medicines Targeting G Protein-Coupled Receptors Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults

Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence Novo Nordisk Invests 42 Billion Danish Kroner in New Manufacturing Facilities Addex ADX71149 Epilepsy Phase

May 2022 "We are thrilled to announce that our co-founder Margaux Duchamp has been selected as a 30 under

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel

Breakthroughs this week: Decoding ADGRE5 signaling; Eli Lilly’s obesity pill vs Novo’s Wegovy; Certa GPCRs in the spotlight; receptor motion tracking tools; obesity treatment race between Eli Lilly and Novo

This week’s feature goes straight to the foundation: how system-level GPCR thinking  protects discovery Week in Premium: Sneak Peek Industry insights:  Lilly cuts Zepbound prices; Lilly hits $1T valuation; Novo

We’ve shaped everything we do around three interconnected ecosystems: Free , Premium , and Foundry. Strengthening the Foundation You already know our Free Ecosystem  — the podcast, blogs, and Flash News GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr. GPCR Foundry: Science Meets Execution The Foundry is where we bring together biotech innovators, Venture With appreciation and excitement, Yamina Berchiche Founder & CEO, Dr. GPCR About Dr. GPCR Dr.

Your scientific thinking built the foundation, but leadership is what scales it. Let’s unpack the three core “rules” most scientific founders unconsciously carry into their companies In startups, waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay Founders who keep operating like researchers often create internal confusion. The transition between the two isn’t automatic, even for the most capable founders.

Biologics announce manufacturing agreement  to advance novel anti-CCR8 antibody  for cancer immunotherapy Novo

Therapeutics with Generative AI Nxera Pharma receives approval of insomnia drug in Japan Lilly and Novo and UK and Announces the Nomination of Clinical Candidate Against MC2 Call for GPCR Papers Deadline: Nov

Welcome to Terry’s Corner , where foundational pharmacology is demystified by someone who’s spent over just look at the data—learn how to read the story it’s telling. 👉 Start your journey with Terry’s foundational

Industry insights:  Fresh selectivity datasets on openMe; Novo’s obesity dominance faces new challengers

In this foundational lesson, Terry Kenakin dives deep into a widely used, often misunderstood tool in interpretive tools to ask smarter questions, avoid missteps, and use calcium assays with strategic clarity. 📍 Foundational

31 December 2022 Addex Raises $5.0 Million in Equity Financing Testing the limits of SMILES-based de novo